



Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Hiroyuki Okuzawa, Representative Director,

President and COO

(Code no.: 4568, Prime Market, Tokyo Stock Exchange)

Please address inquiries to Kentaro Asakura,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126 https://www.daiichisankyo.com

Daiichi Sankyo Appeals Amended Texas Court Judgement in Patent Dispute with Seagen

Tokyo – (**November 17, 2023**) – Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit seeking review of the amended final judgment entered on October 17, 2023 by the U.S. District Court for the Eastern District of Texas in a patent litigation filed by Seagen Inc. against Daiichi Sankyo.

The District Court's amended final judgment requires Daiichi Sankyo to pay Seagen Inc. a royalty of 8% on sales of ENHERTU® from April 1, 2022 through November 4, 2024, when U.S. Patent 10,808,039 expires. This award was in addition to the \$41.8 million in damages previously awarded by the Court following the jury's verdict. The District Court entered the amended final judgment after its denial of Daiichi Sankyo's motions for judgment as a matter of law, or alternatively, a new trial, which Daiichi Sankyo had made in response to the April 8, 2022 jury verdict, and its resolution of motions seeking clarification of prior orders.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.